Researchers in our Division of Rheumatology are striving to better define the molecular and genetic basis for autoimmune diseases such as lupus and arthritis.

Recent advancements:

Removal of immune complexes in lupus

Dr. Keith Elkon, head of the Division of Rheumatology, is researching how to better define the molecular basis for systemic autoimmune diseases such as lupus. He has made a number of findings linking certain autoantibodies to disease, apoptotic cell fragments to inflammation and has identified mechanisms that lead to overproduction of type 1 interferons in lupus and other autoimmune disorders. He is co-founder of a UW startup, Resolve Therapeutics, dedicated to removal of harmful immune complexes in lupus. He is currently working on small molecule inhibitors of interferon pathways.